FDA Approves Second Dose of Moderna’s COVID-19 Vaccine
FDA Declines Eli Lilly’s Letter for Non-Small Cell Lung Cancer Drug
FDA Approves Bristol Myers Antibody Combination for Melanoma
J&J’s Global Initiatives Improve Disease Detection, Broaden Access
Pfizer’s Ulcerative Colitis Drug Helps Patients in Phase 3 Study
Vivalink’s Biometrics Data Platform Monitors Oncology Patients
Moderna Will Expand mRNA Vaccine Pipeline Through 2 New Programs
Sandoz Acquires Drug Delivery Device Company to Boost Pipeline
Thermo Fisher to Invest $97M to Expand Drug Development Efforts
Pfizer Submits for EUA of Additional COVID-19 Vaccine Booster
Keytruda Boosts Survival Rate for Non-Small Cell Lung Cancer
Novavax Launches 2 Global Vaccine Programs As Educational Tools
AstraZeneca Launches R&D Challenge to Advance Drug Discovery
Boehringer Ingelheim Halts Chronic Kidney Disease Trial
Moderna Doses First Patient in HIV mRNA Vaccine Clinical Trial
Civica to Manufacture Lower-Priced Insulin for Diabetes Patients
Pfizer’s C. Difficile Vaccine Misses Primary Endpoint in Trial
Novo Nordisk Expands Collaboration in Oral Drug Delivery Tech
Pfizer Initiates Phase 2/3 Clinical Trial of COVID-19 Treatment
FDA Approves Boehringer Ingelheim’s Heart Failure Treatment
Moderna Launches Public Health Strategy to Advance mRNA Vaccines
Gilead’s Trodelvy Helps HR/HER2 Metastatic Breast Cancer Patients
AMA Supports Biden’s Medicare Proposal, Prescription Drug Policies
FDA Issues 3 Cancer Clinical Trial Final Guidance Documents
Boehringer Ingelheim, Lifebit Partner to Advance Biomedical Data
FDA Rejects Gilead’s Drug Application for HIV-1 Treatment
UC Berkeley Loses CRISPR Gene-Editing Patent Appeal
AstraZeneca, Alexion, Neurimmune to Develop Rare Disease Antibody
FDA Accepts Bristol Myers’s BLA for Non-Small Cell Lung Cancer Drug
FDA Accepts Application for Pfizer’s Biosimilar to Humira
Nearly Half of All Medicare Drug Prices Increased From 2019-2020
CHMP Recommends Pfizer, Biohaven’s Generic Drug for Migraine Attacks
ACIP Recommends Pfizer’s TBE Vaccine For Individuals Most At Risk
Moderna, Thermo Fisher to Boost mRNA Vaccine Manufacturing